Work

Abstract 4596: The combination of the AR PROTAC AZD9750 and AKT inhibitor capivasertib delivers improved efficacy over monotherapy in prostate cancer

Year: 2026

Type: conference-abstract

Source: Cancer Research

DOI: 10.1158/1538-7445.am2026-4596

Authors: Antonio Ramos-Montoya, Chrysiis Michaloglou, Nuria Galeano-Dalmau, Ana Quiroga, Michael Niedbala, Claire Crafter

Institutions: AstraZeneca (United Kingdom), AstraZeneca (United States)

Language: English

Topic: Prostate Cancer Treatment and Research

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W7148858952

Cites:

Cited by:

Related to: